Company / Accounts Receivable
CHINA PHARMA HOLDINGS, INC. Accounts Receivable History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$241.4K
FY2025
5-year range
$232.1K / $504.4K
FY2022-FY2025
Trend
+4.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $504,448 to $241,412 over the past 2 years.
Based on SEC 10-K filings.
$241,412 in FY2025 with a 3-year CAGR of -17.0%.
Declined from $504,448 to $241,412 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -17.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -17.0%, indicating a declining trend.
- In FY2025, accounts receivable increased 4.0% year-over-year.
Company context
Key Data Points
- Altman Z-Score -0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $241.4K | +4.0% |
| FY2024 | $232.1K | -54.0% |
| FY2023 | $504.4K | +19.7% |
| FY2022 | $421.5K | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026